[NEWS RELEASEystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 -mpany reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XIAN, CHINA November 16, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights Revenuereases 45% YoY to record $18.5 million]
[SCHEDULE 13D/A CUSIP No. Page 2 1 NAME OF REPORTING PERSONS Warburg Pincus Private Equity X, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP ¨ (a) (b)]
[Tianyin Reports Record First Quarter Fiscal Year 2011 Financial Results Press Release Source Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals announced financial results for the first quarter of Fiscal Year 2011. First quarter fiscal year 2011 ending September 30, 2010 financial highlights] [Tianyin Pharmaceutical, Inc. First Quarter Fiscal Year 2011 Earnings Results November 11, 2010 Operator: Ladies and gentlemen, thank you for standing by and welcome to the Tianyin Pharmaceutical, Inc. Fiscal Year 2010 Earnings conference call. During today’s presentation all parties will be in a listen-only mode. Following the presentation the conference will be open for questions. If you have a] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 11, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 7 –]
[SCHEDULE 13D/A CUSIP No. Page 2 1 NAME OF REPORTING PERSONS Warburg Pincus Private Equity X, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP ¨ (a) (b)]
[Tianyin Reports Record First Quarter Fiscal Year 2011 Financial Results Press Release Source Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals announced financial results for the first quarter of Fiscal Year 2011. First quarter fiscal year 2011 ending September 30, 2010 financial highlights] [Tianyin Pharmaceutical, Inc. First Quarter Fiscal Year 2011 Earnings Results November 11, 2010 Operator: Ladies and gentlemen, thank you for standing by and welcome to the Tianyin Pharmaceutical, Inc. Fiscal Year 2010 Earnings conference call. During today’s presentation all parties will be in a listen-only mode. Following the presentation the conference will be open for questions. If you have a] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 11, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 7 –]
[Sinovac Reports Unaudited Third Quarter 2010 Financial Results - Conference call scheduled for Monday, November 15, 2010 at 8:00 AM EST Beijing November 15, 2010 Sinovac Biotech Ltd. ( NASDAQ: SVA), a leading provider of biopharmaceutical products in China , announc ed today its un audited financial results for the three-month and nine-month periods ended September 30,] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number PART I. FINANCIAL INFORMATION Item 1.] [CERTIFICATE OF AMENDMENT AND CERTIFICATE OF CHANGE EX-3.1 3 v202562_ex3-1.htm] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Michael H. Lan, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 37 v202562_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 38 v202562_ex32-2.htm]
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number PART I. FINANCIAL INFORMATION Item 1.] [CERTIFICATE OF AMENDMENT AND CERTIFICATE OF CHANGE EX-3.1 3 v202562_ex3-1.htm] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Michael H. Lan, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 37 v202562_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 38 v202562_ex32-2.htm]
[BIOSTAR PHARMACEUTICALS, INC. REPORTS THIRD QUARTER REVENUE INCREASE OF 29.7% TO $20.2 MILLION XIANYANG, China, November 15, 2010 (Xinhua-PRNewswire-FirstCall) , - Q3 2010 revenue increased 29.7% to $20.2 million - Q3 2010 Non-GAAP adjusted net income increased 11.9% to $3.5 million with Non-GAAP adjusted EPS of $0.13 - Cash and cash equivalents totaled $16.6 million at September 30 - $8.7]
[BIOSTAR PHARMACEUTICALS, INC. REPORTS THIRD QUARTER REVENUE INCREASE OF 29.7% TO $20.2 MILLION XIANYANG, China, November 15, 2010 (Xinhua-PRNewswire-FirstCall) , - Q3 2010 revenue increased 29.7% to $20.2 million - Q3 2010 Non-GAAP adjusted net income increased 11.9% to $3.5 million with Non-GAAP adjusted EPS of $0.13 - Cash and cash equivalents totaled $16.6 million at September 30 - $8.7]
